Tu1650: HCV DIRECT-ACTING ANTIVIRAL THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA: UNDERSTANDING FACTORS ASSOCIATED WITH LOWER SVR RATES | Publicación